(Q37176491)

18 August 2017

1 reference

title

Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome (English)

1 reference

18 August 2017

0 references

0 references

1 reference

P Collins

1

1 reference

18 August 2017

U Budde

2

1 reference

18 August 2017

J H Rand

3

1 reference

18 August 2017

A B Federici

4

1 reference

18 August 2017

C M Kessler

5

1 reference

18 August 2017

publication date

1 July 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

14 Suppl 3

1 reference

18 August 2017

page(s)

49-55

1 reference

A population based, unselected, consecutive cohort of patients with acquired haemophilia A.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Treatment of acquired hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Treatment of acquired haemophilia with factor eight inhibitor bypassing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Monitoring the bioavailability of FEIBA with a thrombin generation assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Immunoadsorption may provide a cost‐effective approach to management of patients with inhibitors to FVIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

DDAVP in acquired hemophilia A: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

A new ELISA assay for diagnosis of acquired von Willebrand Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2008.01745.X

10.1111/J.1365-2516.2008.01745.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference